StockNews.com assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report released on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Several other research analysts also recently weighed in on NKTR. Mizuho restated a neutral rating and issued a $6.00 target price on shares of Nektar Therapeutics in a research note on Monday, August 7th. TD Cowen upgraded shares of Nektar Therapeutics from a market perform rating to an outperform rating in a research note on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Nektar Therapeutics presently has a consensus rating of Hold and an average price target of $3.00.
Nektar Therapeutics Stock Performance
Institutional Trading of Nektar Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Diversified Trust Co purchased a new position in Nektar Therapeutics in the third quarter valued at $36,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of Nektar Therapeutics by 0.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,904,745 shares of the biopharmaceutical company’s stock worth $2,921,000 after purchasing an additional 34,267 shares in the last quarter. RA Capital Management L.P. bought a new stake in Nektar Therapeutics in the third quarter worth approximately $11,138,000. GSA Capital Partners LLP lifted its holdings in Nektar Therapeutics by 931.5% during the 3rd quarter. GSA Capital Partners LLP now owns 1,841,078 shares of the biopharmaceutical company’s stock valued at $1,097,000 after purchasing an additional 1,662,589 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in Nektar Therapeutics by 29.9% during the third quarter. AQR Capital Management LLC now owns 3,666,264 shares of the biopharmaceutical company’s stock valued at $2,184,000 after purchasing an additional 844,644 shares during the period. Institutional investors and hedge funds own 82.20% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.
- Five stocks we like better than Nektar Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- The most upgraded stocks in November have two things in common
- Retail Stocks Investing, Explained
- Monday.com rocked earnings like it’s the weekend
- What Are Meme Stocks and Are They Viable Investments?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.